Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience.

Purpose: To prospectively assess bone marrow (BM) angiogenesis in patients with acute myeloid leukemia (AML) by using iron-oxide-enhanced magnetic resonance (MR) imaging. Materials and Methods: The study was institutional ethics committee approved. Informed signed consent was obtained from each study participant. The requirement for informed consent for use of data from a reference database was waived. Eleven patients (seven women, four men; mean age, 53 years +/- 4.40 [standard deviation]) with an initial diagnosis of AML were enrolled in the study and underwent T2*-weighted two-echo echo-planar MR imaging of the pelvis before and after intravenous injection of a clinically approved iron oxide blood-pool contrast agent. Six healthy control subjects (one woman, five men; mean age, 35 years +/- 2.31) were examined with the same MR protocol. The iron oxide-induced change in R2* relaxation rate (Delta R2*) was calculated, and the vascular volume fraction (VVF) of the BM was derived by dividing the Delta R2* of the BM by the Delta R2* of the muscle. Parametric Delta R2* maps were calculated to visualize vessel distribution. Patients underwent BM biopsy for correlative determination of microvessel density (MVD) and vascular endothelial growth factor (VEGF). Differences in Delta R2*, VVF, VEGF, and MVD were compared by using the Wilcoxon rank sum test. Results: Delta R2* maps showed prominent areas of highly vascularized BM in the patients with AML, whereas the control subjects had moderately vascularized BM with homogenous vessel distribution. Qualitative analysis revealed VVF values to be significantly higher in patients with AML than in control subjects: The mean VVF in the pelvis was 9.18% +/- 1.54 for patients versus 3.91% +/- 0.61 for control subjects (P = .010). In accordance with MR results, MVD (P = .009) and VEGF expression (P = 0.17) were significantly elevated in the AML group compared with values in the control group. Conclusion: Iron oxide-enhanced MR imaging enables assessment of BM angiogenesis in patients with AML.